Elicio Therapeutics Inc. (ELTX)
NASDAQ: ELTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ELTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $41.05M
- EPS (TTM)
- -$1.81
- Dividend yield
- None
- 52-week range
- 1.25 – 16.00
- Day range
- 1.44 – 1.59
- Volume / Avg
- 231.62K / 324.71K
- Beta
- —
- Shares outstanding
- 28.31M
52-week range
ELTX stock today
Shares of Elicio Therapeutics (ELTX) finished lower on Nov 20 at $1.45, a drop of 3.33% or $0.05 per share, versus the S&P 500's 3.70% decline. Shares are 90.9% below their 52-week high of $16.00, set on Jun 10, 2026 and 16.0% above the 52-week low of $1.25, near the bottom of the past year's range. ELTX is down 81.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 82.8%.
Elicio Therapeutics has posted a net loss over the last twelve months (EPS of -$1.81), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Elicio Therapeutics
Company profileElicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert T. Connelly
- Headquarters
- Boston, MA
- Employees
- 33
- IPO year
- 2021
- Website
- elicio.com
Financial highlights
Full financialsElicio Therapeutics reported a net loss of $39.6 million, compared with a loss of $51.9 million a year earlier. Diluted earnings per share came in at -$2.58.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $2.30M | $28.31M |
| Growth | — | — | — | -91.87% | +883.06% |
| Net income | $-39.57M | $-51.90M | $-35.20M | $-28.21M | $-54.57M |
| EPS (diluted) | $-2.58 | $-4.25 | $-6.96 | $-89.27 | $-1.93 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$13.67+842.76%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.30 vs $-0.42
- Surprise
- +28.57%
ELTX news
All ELTX news- Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual MeetingGlobeNewswire
- Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature MedicineGlobeNewswire
Elicio Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TLPHTalphera Inc. | 0.7852 | +6.25% | $40.80M | vs ELTX |
| MREOMereo BioPharma Group plc ADR | 0.26 | -5.45% | $41.52M | vs ELTX |
| BMEABiomea Fusion Inc. | 0.5744 | -2.38% | $41.75M | vs ELTX |
| OSTXOS Therapies Incorporated | 0.803 | -2.12% | $42.00M | vs ELTX |
| INCRIntercure Ltd. | 3.24 | -7.69% | $42.03M | vs ELTX |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 2.06 | -15.40% | $42.45M | vs ELTX |
| DWTXDogwood Therapeutics Inc. | 1.04 | -2.36% | $39.57M | vs ELTX |
| SPROSpero Therapeutics Inc. | 0.742 | -10.20% | $43.23M | vs ELTX |
Indexes, lists and sector
Elicio Therapeutics stock FAQ
What is Elicio Therapeutics's stock price today?
ELTX last traded at $1.45 as of Nov 20, 4:00 PM EST, down 3.33% on the day. Prices are delayed at least 15 minutes.
Does Elicio Therapeutics pay a dividend?
No. Elicio Therapeutics does not currently pay a regular cash dividend.
Who is Elicio Therapeutics's CEO?
Mr. Robert T. Connelly is the chief executive officer of Elicio Therapeutics Inc., which has about 33 employees.
Has ELTX ever split its stock?
Yes. The most recent ELTX stock split was a 1-for-10 split on Jun 2, 2023.
What is the ELTX 52-week high?
The 52-week high for ELTX is $16.00 and the 52-week low is $1.25. The stock is currently 90.9% below its high.